Biomea Fusion (BMEA) vs Dogwood Therapeutics (DWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 41.5% versus a loss of 83.7%. Over five years, BMEA leads with a -95.2% price change compared with -99.2% for DWTX. Biomea Fusion is the larger company by market cap ($41.7 million vs $39.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | DWTX |
|---|---|---|
| Share price | $0.5744 | $1.04 |
| Market cap | $41.75M | $39.57M |
| 1-day change | -2.38% | -2.36% |
| YTD return | -53.68% | -75.12% |
| 1-year return | -41.51% | -83.68% |
| 5-year return | -95.21% | -99.16% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-0.10 | $10.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | $-34.26M |
| 52-week high | $2.24 | $7.04 |
| 52-week low | $0.45 | $0.901 |
| Distance from 52-week high | -74.32% | -85.31% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1118.66% | +1252.66% |
| Average volume | 2.22M | 89.88K |
| Shares outstanding | 72.68M | 38.23M |
| Employees | 37 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed DWTX by 42.2 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
BMEA vs DWTX FAQ
Which is bigger, Biomea Fusion or Dogwood Therapeutics?
Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $39.57M for Dogwood Therapeutics (DWTX).
Which stock has performed better over the past year, BMEA or DWTX?
BMEA returned -41.51% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Dogwood Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.